DigiWest® Protein Profiling Services
New! Feb'19: Our new "Pathway Activity Panels" are designed to profile activation/ phosphorylation of key cell signaling pathways (RTK/RAS/RAF/ERK, PI3K/AKT, mTOR). As these pathways are frequently targeted by anti-cancer drugs, our Pathway Activity Panels are valuable for both clinical and pre-clinical samples. Contact us to get the list!
New! Jan'19: We have just established DigiWest® for FFPE (formalin-fixed paraffin-embedded) samples! Get in contact to see our list of 175+ suitable antibodies.
DigiWest® immuno-assays enable comprehensive analyses of up to 800 total and phospho proteins using just ~60 µg of total protein, from 2D or 3D cells, xenografts, tissues or even sections (e.g. LCM)
DigiWest® studies are fully customizable, based on a list of currently 1,215 antibodies, including 389 antibodies against phospho-epitopes and other post-translational modifications (PTMs), with 50+ pre-defined pathway panels for human, mouse, rat, dog, cyno & minipig samples
DigiWest® represents a versatile platform for pathway profiling, drug MoA studies, compound characterization (small molecules, PROTACs, antibodies, etc.), biomarker discovery, and safety/tox
DigiWest® combines the robustness of Western blotting with the power of Luminex® bead-based multiplexing, and has been invented, developed and validated by Dr. Markus Templin's group at NMI
DigiWest® is being offered on a fee-for-service basis
Imagine to get data on 80, 300, or even 800 total & phospho proteins from just 10-60 micrograms of protein sample. With DigiWest® you can!
Case study 1: DigiWest® for biomarker discovery
Analysis of mechanisms and biomarkers of platinum resistance
A set of 24 fresh frozen tumor specimens from relapsed vs cured platinum-treated ovarian cancer patients was analysed by DigiWest®, using 466 antibodies (total and phospho proteins) covering various cell signalling pathways.
DigiWest® protein signatures distinguished platinum resistant vs sensitive patients, and revealed 8 promising biomarker candidates.
Case study 2: DigiWest® for lead characterization
Mode-of-action study of compounds in comparison to reference drugs
Calu1 cells were treated with 1 MEK inhibitor vs 1 PI3K inhibitor vs 2 experimental lead compounds (data not shown) vs DMSO. Cell samples were analysed by DigiWest®, using 156 selected antibodies (total and phospho proteins) covering different signal transduction pathways.
DigiWest® yielded distinct signatures for each compound, and allowed in-depth characterization of lead compounds as compared to reference drugs.
Case study 3: DigiWest® in PD3D® tumor models
Protein profiling for characterization of primary tumor samples
In collaboration with cpo Cellular Phenomics & Oncology GmbH, primary patient-derived 3D tumor cell cultures (PD3D®) were profiled by DigiWest®, focusing on 122 antibodies for total and phospho proteins involved in a range of signaling pathways.
DigiWest® revealed pathway activation patterns that explained phenotypic differences in PD3D® drug responses as measured by cpo.
Case study 4: DigiWest® in multiple species
Multiplex protein profiling for safety/toxicology and in vivo pharmacology
A DigiWest® panel of >700 antibodies previously validated in human and mouse materials was tested in protein lysates from liver and kidney samples of rat, dog, minipig and cynomolgus origin.
This comprehensive validation project has yielded hundreds of antibodies for DigiWest® and Western blot studies, thus enabling protein profiling in safety/toxicology and in vivo pharmacology.
Sikorski K, et al. A high-throughput pipeline for validation of antibodies. Nature Methods 2018
Mehul B, et al. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from [...] treated HuT78 CTCL cell line. Journal of Proteomics 2018
Lomnytska M, et al. Platelet protein biomarker panel for ovarian cancer diagnosis. Biomarker Research 2018
De Boussac H, et al. Epidermal Growth Factor represses CAR expression in primary hepatocytes and favors regulation by PXR. Drug Metab Dispos 2017
Kissel M, et al. Antitumor effects of [...] in preclinical models of hepatocellular carcinoma. Oncotarget 2017
Mishra M, et al. Protein purification and analysis: next generation Western blotting techniques. Expert Rev Proteomics 2017
Menck K, et al. Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane. J Extracell Vesicles 2017
Augustin I, et al. Autocrine Wnt regulates the survival and genomic stability of embryonic stem cells. Science Signaling 2017
Treindl F, et al. A bead-based western for high-throughput cellular signal transduction analyses. Nature Communications 2016
DigiWest: Multiplex profiling of proteins for biomarker discovery. LabsExplorer 2018
Sachse C, Templin M. Multiplexing Western blots: More data, less sample. GEN 2018
Erdmann G, et al. Towards 3Rs: Multiplex protein profiling from minipig, cyno, dog and rat samples, to get the most our of preclinical safety studies. Ellegaard Newsletter 2018
Graham H. Drop the blot: Parallel quantification of up to 800 proteins. Luminex Blog 2018
Singh G. The future of now - how the science of today shapes tomorrow. ScienceExchange Blog 2018
Pearson S. Screening innovations and 3D assay developments showcased at ELRIG. GEN 2017
Sachse C, Regenbrecht CRA, Templin MF. Beyond Genomics. DigiWest-Technologie: Multiplex-Analyse von Proteinen und Phosphoproteinen. LABO 2017
How to find the missing link between genotype and phenotype. Labiotech 2017
Evans J. A blot on the beads: Western blotting with a bead-based immunoassay. Electrophoresis 2016
Couvillon A, Templin MF. Cross-validation of antibodies using DigiWest. LabRoots 2016
Graham H. DigiWest: Reimaging Western blotting on the proteomic scale. Luminex 2016